CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,558 | -24.1% | 34,331 | -6.1% | 0.02% | -11.8% |
| Q2 2023 | $2,053 | -14.1% | 36,563 | -30.8% | 0.02% | -15.0% |
| Q1 2023 | $2,389 | +131.0% | 52,820 | +107.6% | 0.02% | +33.3% |
| Q4 2022 | $1,034 | -99.9% | 25,441 | +47.7% | 0.02% | 0.0% |
| Q3 2022 | $1,125,000 | -4.3% | 17,220 | +10.9% | 0.02% | +25.0% |
| Q4 2021 | $1,176,000 | +13.6% | 15,522 | +67.9% | 0.01% | -14.3% |
| Q3 2021 | $1,035,000 | +238.2% | 9,246 | +267.8% | 0.01% | +250.0% |
| Q1 2021 | $306,000 | -65.8% | 2,514 | -57.0% | 0.00% | -55.6% |
| Q4 2020 | $894,000 | +237.4% | 5,842 | -6.4% | 0.01% | -40.0% |
| Q1 2020 | $265,000 | – | 6,242 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |